Elicio Therapeutics and Angion Enter into Definitive Merger AgreementJanuary 17th, 2023
FiledJanuary 17th, 2023Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology